Karnofsky Performance Status Scale
Karnofsky Performance Status (KPS) scale rates functional capacity on a 100-point scale in 10-point increments. Used in oncology for treatment decisions, prognosis, and clinical trial eligibility.
Score interpretation
Able to carry on normal activity with minor limitations. Corresponds to ECOG 0–1.
→ Eligible for standard chemotherapy. Most clinical trials require KPS ≥ 70. Treatment can proceed with standard doses.
Unable to work or carry on normal activity; requires some help. Corresponds to ECOG 2–3.
→ Careful assessment before intensive chemotherapy. Consider reduced-intensity regimens. MDT discussion. Palliative intent if KPS < 60.
Requires significant support; hospitalisation likely. Corresponds to ECOG 3–4.
→ Palliative/supportive care focus. Active treatment rarely tolerated or beneficial. Comfort measures, symptom management, advance care planning.
Interpretation bands for the Karnofsky Score. Apply clinical judgement and local guidance.
References
- Karnofsky DA, Burchenal JH. The clinical evaluation of chemotherapeutic agents in cancer. In: MacLeod CM, ed. Evaluation of Chemotherapeutic Agents. Columbia University Press, 1949.
Related
Curated clinical cross-links plus same-class fallbacks.
- Folinic Acid (Calcium Folinate / Leucovorin) · Antidote / Chemotherapy Support
- Phenytoin / Fosphenytoin · Antiepileptic — Status Epilepticus (Second-Line)
- Levetiracetam (IV) · Antiepileptic — Status Epilepticus (Second-Line)
- Zoledronic Acid · Bisphosphonate (IV)
- Denosumab · RANK Ligand Inhibitor (Anti-resorptive)
- Cisplatin · Platinum Chemotherapy — Head and Neck Cancer
- Major Haemorrhage / Massive Transfusion · BCSH; RCOA; RCEM; RCS — BCSH Guidelines
- Anaemia Investigation · BSH / NICE
- Splenomegaly Workup · BSH; BMJ Best Practice
- Deep Vein Thrombosis Diagnosis and Treatment · NICE CG144 / NICE NG158
- Sickle Cell Crisis · BSH 2021 / BCSH
- Neutropenic Sepsis · NICE CG151 2012 / ESMO
Decision support only — verify against a current formulary, NICE, or your local guideline before clinical use.